Study S002138

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07225686
Acronym: MARITIME-OSA-1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 250
Start: 2025-12-19
Primary completion: 2027-08-20
Lead sponsor: Amgen
Conditions: Obesity; Obstructive Sleep Apnea
Interventions: DRUG:Maridebart cafraglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change in Apnea-Hypopnea Index (AHI) from baseline at week 52 [At week 52]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.